Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis
ObjectiveTo present the pooled quantitative evidence of baseline characteristics and clinical outcomes of tocilizumab (TCZ) in patients with refractory Takayasu arteritis (TAK).MethodsA comprehensive systematic review and meta-analysis was performed on all available studies retrieved from the MEDLIN...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1084558/full |
| _version_ | 1828039438403371008 |
|---|---|
| author | Limei Kang Yang Liu Zhongling Luo Yueyuan Zhou Bo Chen Geng Yin Qibing Xie |
| author_facet | Limei Kang Yang Liu Zhongling Luo Yueyuan Zhou Bo Chen Geng Yin Qibing Xie |
| author_sort | Limei Kang |
| collection | DOAJ |
| description | ObjectiveTo present the pooled quantitative evidence of baseline characteristics and clinical outcomes of tocilizumab (TCZ) in patients with refractory Takayasu arteritis (TAK).MethodsA comprehensive systematic review and meta-analysis was performed on all available studies retrieved from the MEDLINE, Embase, and Cochrane databases, using TCZ in patients with refractory TAK. We applied the commands metan and metaprop_one in Stata Software to pool overall estimates of continuous data and binomial data, respectively. A random-effects model was recruited for analysis.ResultsNineteen studies with 466 patients were included in this meta-analysis. The mean age at implementation of TCZ was 34.32 years. Female sex and Numano Type V were the most prominent baseline characteristics. During the 12-month follow-up when receiving TCZ treatment, pooled CRP was 1.17 mg/L (95% confidence interval [CI] -0.18-2.52), pooled ESR was 3.54 mm/h (95% CI 0.51-6.58), and pooled glucocorticoid dose was 6.26 mg/d (95% CI 4.24-8.27). Approximately 76% (95% CI 58-87%) of patients achieved a decrease in glucocorticoid dosage. Meanwhile, patients with TAK had a remission rate of 79% (95% CI 69-86%), a relapse rate of 17% (95% CI 5-45%), an imaging progress rate of 16% (95% CI 9-27%), and a retention rate of 68% (95% CI 50-82%). Adverse events occurred in 16% (95% CI 5-39%) of patients, and infection was the most common adverse event, with a rate of 12% (95% CI 5-28%).ConclusionTCZ treatment can provide favorable outcomes in terms of inflammatory markers, steroid-sparing effects, clinical response, drug retention and minimizing adverse effects for patients with refractory TAK. |
| first_indexed | 2024-04-10T16:42:07Z |
| format | Article |
| id | doaj.art-67cf2de86d9348a7ac11172ac32453b7 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T16:42:07Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-67cf2de86d9348a7ac11172ac32453b72023-02-08T06:40:44ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-02-011410.3389/fimmu.2023.10845581084558Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritisLimei Kang0Yang Liu1Zhongling Luo2Yueyuan Zhou3Bo Chen4Geng Yin5Qibing Xie6Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Vascular Surgery, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of General Practice, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, ChinaObjectiveTo present the pooled quantitative evidence of baseline characteristics and clinical outcomes of tocilizumab (TCZ) in patients with refractory Takayasu arteritis (TAK).MethodsA comprehensive systematic review and meta-analysis was performed on all available studies retrieved from the MEDLINE, Embase, and Cochrane databases, using TCZ in patients with refractory TAK. We applied the commands metan and metaprop_one in Stata Software to pool overall estimates of continuous data and binomial data, respectively. A random-effects model was recruited for analysis.ResultsNineteen studies with 466 patients were included in this meta-analysis. The mean age at implementation of TCZ was 34.32 years. Female sex and Numano Type V were the most prominent baseline characteristics. During the 12-month follow-up when receiving TCZ treatment, pooled CRP was 1.17 mg/L (95% confidence interval [CI] -0.18-2.52), pooled ESR was 3.54 mm/h (95% CI 0.51-6.58), and pooled glucocorticoid dose was 6.26 mg/d (95% CI 4.24-8.27). Approximately 76% (95% CI 58-87%) of patients achieved a decrease in glucocorticoid dosage. Meanwhile, patients with TAK had a remission rate of 79% (95% CI 69-86%), a relapse rate of 17% (95% CI 5-45%), an imaging progress rate of 16% (95% CI 9-27%), and a retention rate of 68% (95% CI 50-82%). Adverse events occurred in 16% (95% CI 5-39%) of patients, and infection was the most common adverse event, with a rate of 12% (95% CI 5-28%).ConclusionTCZ treatment can provide favorable outcomes in terms of inflammatory markers, steroid-sparing effects, clinical response, drug retention and minimizing adverse effects for patients with refractory TAK.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1084558/fulltocilizumabTakayasu arteritisrefractorybaseline characteristicclinical outcome |
| spellingShingle | Limei Kang Yang Liu Zhongling Luo Yueyuan Zhou Bo Chen Geng Yin Qibing Xie Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis Frontiers in Immunology tocilizumab Takayasu arteritis refractory baseline characteristic clinical outcome |
| title | Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis |
| title_full | Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis |
| title_fullStr | Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis |
| title_full_unstemmed | Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis |
| title_short | Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis |
| title_sort | systematic review and meta analysis of the current literature on tocilizumab in patients with refractory takayasu arteritis |
| topic | tocilizumab Takayasu arteritis refractory baseline characteristic clinical outcome |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1084558/full |
| work_keys_str_mv | AT limeikang systematicreviewandmetaanalysisofthecurrentliteratureontocilizumabinpatientswithrefractorytakayasuarteritis AT yangliu systematicreviewandmetaanalysisofthecurrentliteratureontocilizumabinpatientswithrefractorytakayasuarteritis AT zhonglingluo systematicreviewandmetaanalysisofthecurrentliteratureontocilizumabinpatientswithrefractorytakayasuarteritis AT yueyuanzhou systematicreviewandmetaanalysisofthecurrentliteratureontocilizumabinpatientswithrefractorytakayasuarteritis AT bochen systematicreviewandmetaanalysisofthecurrentliteratureontocilizumabinpatientswithrefractorytakayasuarteritis AT gengyin systematicreviewandmetaanalysisofthecurrentliteratureontocilizumabinpatientswithrefractorytakayasuarteritis AT qibingxie systematicreviewandmetaanalysisofthecurrentliteratureontocilizumabinpatientswithrefractorytakayasuarteritis |